Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Neoplasms 2Multiple Myeloma 1Melanoma 1Lymphoma, B-Cell 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1B-Cell Malignancies 1Advanced Solid Malignancies 1

Interventions

Cisplatin 35pembrolizumab 29Radiotherapy 26Cetuximab 26Docetaxel 17Paclitaxel 13Fluorouracil 13Cyclophosphamide 12fludarabine 11Radiotherapy, Intensity-Modulated 11Nivolumab 10Carboplatin 9atezolizumab 7Radiation 7Gemcitabine 7Erlotinib Hydrochloride 7Bortezomib 7fludarabine phosphate 6Pemetrexed 5Interleukin-2 5Radiosurgery 4Everolimus 4Drug Therapy 4Azacitidine 4olaparib 3motexafin gadolinium 3durvalumab 3cemiplimab 3Trastuzumab 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Head and Neck Neoplasms × urelumab × Clear all
NCT02110082 2017-04-19

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Bristol-Myers Squibb

Phase 1 Completed
66 enrolled
GastrointestinalHead & Neck

Head and Neck Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡